Cantor Fitzgerald Predicts Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Mesoblast in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will earn ($0.70) per share for the year. The consensus estimate for Mesoblast’s current full-year earnings is ($0.74) per share.

MESO has been the subject of a number of other reports. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler boosted their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Stock Down 2.5 %

Shares of NASDAQ:MESO opened at $17.58 on Thursday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 12 month low of $1.72 and a 12 month high of $22.00. The firm’s 50-day moving average is $14.51 and its 200 day moving average is $10.06.

Institutional Trading of Mesoblast

Several institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd purchased a new position in Mesoblast during the 4th quarter valued at about $30,000. Ballentine Partners LLC bought a new position in Mesoblast in the fourth quarter worth approximately $222,000. GAMMA Investing LLC lifted its holdings in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after buying an additional 1,213 shares during the period. Jane Street Group LLC lifted its holdings in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares during the period. Finally, XY Capital Ltd bought a new stake in Mesoblast during the 3rd quarter valued at $244,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.